Natera is turning tumor-informed cfDNA diagnostics into a scalable precision-medicine platform, with explosive oncology growth, improving margins, and Japan expansion offset by near-term losses, litigation, and supply-chain risk.
Overview
Natera is a leading cfDNA diagnostics platform spanning women’s health, oncology, and organ transplant monitoring. The company processed over one million tests in Q1 2026 and grew revenue 38.8% to $696.6 million, demonstrating strong demand and operational scale. Signatera’s personalized tumor-informed MRD approach differentiates Natera in cancer monitoring, while Panorama, Horizon, Fetal Focus, and Prospera broaden its clinical reach. U.S. revenues dominate today, but Japan approval could materially expand the oncology opportunity.